Eupraxia Pharmaceuticals (EPRX) Shares Outstanding (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Shares Outstanding (Entity) of $56.7 million for Q1 2026, up 58.92% year-over-year from $35.7 million in Q1 2025, and up 41.94% quarter-over-quarter from $40.0 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Shares Outstanding (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Shares Outstanding (Entity) for 5 consecutive years, with $56.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 58.92% year-over-year to $56.7 million; the TTM figure through Mar 2026 stood at $56.7 million (up 58.92% YoY), while the FY2025 annual figure was $40.0 million, up 12.11% from the prior year.
- Shares Outstanding (Entity) climbed to $56.7 million in Q1 2026 per EPRX's latest filing, from $40.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $56.7 million in Q1 2026 and bottomed at $21.6 million in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $32.8 million across 5 years, with a median of $35.6 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 61.85% — and 2025, when it climbed 0.81%.
- Eupraxia Pharmaceuticals' Shares Outstanding (Entity) stood at $21.6 million in 2022, then climbed by 26.35% to $27.3 million in 2023, then soared by 30.64% to $35.6 million in 2024, then climbed by 12.11% to $40.0 million in 2025, then surged by 41.94% to $56.7 million in 2026.
- Business Quant data shows EPRX's Shares Outstanding (Entity) at $56.7 million in Q1 2026, $40.0 million in Q4 2025, and $36.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 56.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.71 Mn |
| Dec 31, 2025 | 39.96 Mn |
| Sep 30, 2025 | 36.92 Mn |
| Jun 30, 2025 | 35.91 Mn |
| Mar 31, 2025 | 35.69 Mn |
| Dec 31, 2024 | 33.93 Mn |
| Sep 30, 2024 | 35.62 Mn |
| Jun 30, 2024 | 35.62 Mn |
| Mar 31, 2024 | 28.81 Mn |
| Dec 31, 2023 | 24.15 Mn |
| Sep 30, 2023 | 25.52 Mn |
| Jun 30, 2023 | 22.01 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 19.29 Mn |